Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26217266 | 1.00 | CCNA2 (0.36) | CCNA2CDK2MAPK3MAPK1SMG1 | |
| SCHEMBL20436641 | 0.99 | CCNA2 (0.36) | CCNA2CDK2MAPK3MAPK1SMG1 | |
| SCHEMBL20436733 | 0.99 | CCNA2 (0.36) | CCNA2CDK2MAPK3MAPK1SMG1 | |
| SCHEMBL20417025 | 0.92 | CNR1 (0.38) | LRRK2CNR1MAP4K1PRKCQ | |
| SCHEMBL20436732 | 0.90 | HDAC2 (0.36) | LRRK2CNR1MAP4K1PRKCQ | |
| SCHEMBL20417012 | 0.89 | MAPK1 (0.36) | CCNA2CDK2MAPK3MAPK1LRRK2 | |
| SCHEMBL20417129 | 0.89 | MAPK1 (0.36) | CCNA2CDK2MAPK3MAPK1LRRK2 | |
| SCHEMBL20421964 | 0.89 | MAPK1 (0.36) | CCNA2CDK2MAPK3MAPK1LRRK2 | |
| SCHEMBL30402011 | 0.89 | MAPK1 (0.36) | CCNA2CDK2MAPK3MAPK1LRRK2 | |
| SCHEMBL20436642 | 0.88 | MAPK1 (0.37) | CCNA2CDK2MAPK3MAPK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3570844-B1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |